CMG Pharmaceutical Decides to Issue 45 Billion Won 9th Series CB for Refinancing, Raising Dilution Concerns

CMG Pharmaceutical has decided to issue 45 billion won in 9th series unregistered unsecured private convertible bonds.
The proceeds will be used entirely to repay the existing 8th series convertible bonds, a refinancing move.
The conversion price is set at 968 won, adjustable down to 872 won under market decline, and conversion would add approximately 46.49 million shares, a 23.89% dilution relative to outstanding shares.
The bonds include put and call options, and the buyers are funds managed by major securities firms such as Shinhan, NH, Samsung, KB, Korea Investment, and Mirae Asset.
[AI Summary]CMG Pharmaceutical's CB issuance is a defensive refinancing, but the potential dilution of nearly 24% from conversion and further adjustment risk weigh on the stock. Without growth-oriented use of proceeds, shareholder value enhancement is limited.